Kazia gains as brain cancer drug increases survival in mid-to-late stage study

Kazia Therapeutics

10/07/2024 15:20

** Kazia Therapeutics'  KZIA.O  shares more than double to a
more than two-month high of $0.39; last up 57.1%
    ** Stock set for best day in nearly five years if gains hold
    ** Drug developer says in a mid-to-late stage study, its
experimental drug paxalisib increased survival by 3.8 months vs
standard of care in patients with glioblastoma
    ** Glioblastoma is a type of cancer that starts as a growth
of cells in the brain 
    ** YTD, stock down 31.4%

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com))